Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,634,927 papers from all fields of science
Search
Sign In
Create Free Account
zanolimumab
Known as:
Anti-CD4 Monoclonal Antibody HuMax
, HuMax-CD4
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Monoclonal Antibodies
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Comparison of different methods of thrombus permeability measurement and impact on recanalization in the INTERRSeCT multinational multicenter prospective cohort study
H. Gensicke
,
J. Evans
,
+17 authors
B. Menon
Neuroradiology
2019
Corpus ID: 207938043
Purpose To compare the association of different measures of intracranial thrombus permeability on non-contrast computerized…
Expand
2016
2016
BMS bets on targeting IL-8 to enhance cancer immunotherapies
E. Dolgin
Nature Biotechnology
2016
Corpus ID: 205272044
VOLUME 34 NUMBER 10 OCTOBER 2016 NATURE BIOTECHNOLOGY “There’s good scientific evidence that the presence or absence of cells…
Expand
2011
2011
Alemtuzumab‐resistant Sézary syndrome responding to zanolimumab *
A. Alexandroff
,
V. Shpadaruk
,
W. M. Bamford
,
D. B. J. Kennedy
,
R. Burd
,
M. Dyer
British Journal of Haematology
2011
Corpus ID: 35424114
Primary cutaneous T-cell lymphomas (CTCL) are rare malignancies characterized by clonal T-cell infiltrates (Kim et al, 2005…
Expand
2007
2007
Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.
F. d'Amore
,
J. Radford
,
+9 authors
H. Hagberg
2007
Corpus ID: 78982459
Combination chemotherapy has been the basis of treatment for peripheral T-cell lymphoma (PTCL) for many years, but relapses are…
Expand
2007
2007
A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity.
D. Rider
,
C. Havenith
,
+10 authors
D. Alexander
Cancer Research
2007
Corpus ID: 28536156
Zanolimumab is a human IgG1 antibody against CD4, which is in clinical development for the treatment of cutaneous and nodal T…
Expand
Review
2007
Review
2007
A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
N. Scheinfeld
Journal of Drugs in Dermatology
2007
Corpus ID: 12242354
Dermatologists use a variety of treatments for cutaneous T cell lymphoma (CTCL) or mycosis fungoides, in particular topical…
Expand
2006
2006
Zanolimumab, a fully human monoclonal antibody: preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphomas (PTCL)
F. d'Amore
,
T. Relander
,
+11 authors
O. Baadsgaard
2006
Corpus ID: 71093705
Zanolimumab (previously referred to as HuMax-CD4) is a fully human monoclonal IgG1k antibody. It is specific for the CD4 antigen…
Expand
2004
2004
HuMax-CD4 may induce response in mycosis fungoides
2004
Corpus ID: 195126590
2003
2003
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2003
Corpus ID: 9049018
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2003
2003
HuMax-CD4 for psoriasis: lack of significant results
2003
Corpus ID: 195129987
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE